Prognosis of Disseminated and Cerebral Toxoplasmosis in Intensive Care Evaluating Clinical and Prognostic Differences Using PCR Diagnosis Toxoplasmosis in ICU (TOXIC) Study

What this Trial Is About

Toxoplasmosis is a common infection that can become severe enough to require intensive care, especially in people with weakened immune systems. This research aims to evaluate the effects of different anti-infective treatments and to identify clinical and biological differences as well as prognostic factors based on the type of immune suppression. The study focuses on two main forms of the disease: cerebral toxoplasmosis and disseminated toxoplasmosis, with an emphasis on how diagnosis using PCR has changed management. The study observes patients admitted to intensive care with severe toxoplasmosis confirmed by PCR tests from cerebrospinal fluid, blood, bronchoalveolar lavage, or bone marrow. Treatment regimens, including intravenous and oral combinations of drugs like trimethoprim-sulfamethoxazole, pyrimethamine, sulfadiazine, and clindamycin, are monitored, although the study itself does not administer interventions. The research distinguishes between different patient subgroups based on their underlying immunosuppression to better understand treatment impacts and disease progression. Participants are adults hospitalized in intensive care with at least one organ failure and a positive PCR diagnosis within a week before or after ICU admission. Researchers will monitor mortality rates over an 11-year period and collect clinical and biological data to evaluate disease severity and treatment outcomes. The study seeks to improve early detection, identify new at-risk patient categories, and enhance management of severe toxoplasmosis cases in intensive care units.

Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis